Keeda-Marie Hardisty is Lead Clinical Scientist at Oncologica
Keeda-Marie Hardisty is a clinical scientist with major expertise in Next-Generation Sequencing-based analytics and decision support in oncology. She is responsible for preparing and reviewing data for the creation of clinical reports in conjunction with Oncologica®’s surgical pathologists. Keeda also plans, coordinates and delivers our treatment decision support service for cancer patients and organizes logistics, timely production and communication of the diagnostic reports. Moreover she is involved in the development of workflows and innovative tools to better analyse NGS data for patient care.
Keeda has a broad scope of experience gained from a career that has spanned several genetic disciplines. After gaining her BSc in Forensic Science Keeda worked for the Forensic Science service, focussing on the processing and analysis of samples for DNA based individual identification. In 2008 Keeda moved into the Healthcare sector and qualified as a HCPC registered Clinical Scientist in Molecular Genetics. Keeda’s 5 year career at the Regional Genetics laboratory in North London instilled an in-depth knowledge of germline genetics and the associated technologies. In 2013, Keeda further enhanced her scope by achieving employment at the Royal Marsden Hospital, London. Here under the guidance of Dr David Gonzalez De Castro, Keeda specialised in the Molecular Pathology of Acquired Disease. Keeda delivered personalised patient care using a range of tests and technologies to assess diagnostic, predictive and prognostic markers in solid tumours and haematological malignancies.
Keeda was integral in the implementation of the Cancer Research UK Stratified Medicine programme (SMP2) which employed multigene next generation sequencing panels for the stratification of patients into the National Lung MATRIX trial.
Published Research Papers
Published: March 25, 2022 DOI: https://doi.org/10.1371/journal.pone.0245817
Gareth H Williams, Alexander Llewelyn, Robert Thatcher, Keeda-Marie Hardisty, Marco Loddo
SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom
EClinical Medicine by the Lancet Published:July 14, 2021 DOI: https://doi.org/10.1016/j.eclinm.2021.101021
Gareth H Williams, Alexander Llewelyn, Ruben Brandao, Kaiya Chowdhary,Keeda-Marie Hardisty, Marco Loddo (2021)
J Clin Oncol 38: 2020 (suppl; abstr e13642) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13642
Loddo M, Hardisty KM, Thatcher RP, Haddow TE, Williams GH (2020)
J Clin Oncol 38: 2020 (suppl; abstr e13521) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13521
Williams GH, Thatcher RP, Haddow TE, Hardisty KM, Loddo M (2020)
J Clin Oncol 38: 2020 (suppl; abstr e13517) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13517
Williams GH, Thatcher RP, Nevado B, Haddow TE, Hardisty KM, Loddo M (2020)
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL
Virchows Arch (2016). doi: https://doi.org/10.1007/s00428-016-2025-7.
Zandra C Deans, Jose Luis Costa, Ian Cree, Els Dequeker, Anders Edsjö, Shirley Henderson, Michael Hummel, Marjolijn JL Ligtenberg, Marco Loddo, Jose Carlos Machado, Antonio Marchetti, Katherine Marquis, Joanne Mason, Nicola Normanno, Etienne Rouleau, Ed Schuuring, Keeda-Marie Snelson, Erik Thunnissen, Bastiaan Tops, Gareth Williams, Han van Krieken, Jacqueline A Hall, On behalf of IQN Path ASBL